To evaluate the preventive effect of Bacillus coagulans on acute graft-versus-host disease (aGVHD) after hematopoietic stem cell transplantation
Patients are fully aware of the study, voluntarily participate and sign informed consent;
Age: ≥18 years old;
Patients with hematologic malignancies undergoing allo-HSCT and patients with severe aplastic anemia (SAA) undergoing allo-HSCT were treated with myeloablative conditioning (MAC).
Refused to participate in this clinical study;
Unable to take the drug orally;
Allergic to Bacillus coagulans;
People take allo-HSCT with reduced intensity conditioning (RIC) and nonmyeloablative conditioning (NMC);lymphoma or multiple myeloma with auto-HSCT; multiple myeloma patients.
Parallel
bacillus coagulans combined with the best treatment options for preventing aGVHD
DrugBAT means the best treatment options for preventing aGVHD
BAT
DrugBAT
Rate of acute graft-versus-host disease
Will acute graft-versus-host disease occur within 100 days after hematopoietic stem cell transplantation and its probability of occurrence
Click on the lead sponsor to view all of their trials.
Yamin Fan
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
